October 7, 2020 10:35 AM EDT

News briefing: Pfizer on track to early '22 pivotal readout on hemophilia A; Codiak scales back IPO expectations

ENDPOINTS

Pfizer and Sangamo have dosed their first patient in the Phase III gene therapy trial of giroctocogene fitelparvovec (SB-525) for hemophilia A. Researchers will be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Pfizer on track to early '22 pivotal readout on hemophilia A; Codiak scales back IPO expectations

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

News briefing: Pfizer on track to early '22 pivotal readout on hemophilia A; Codiak scales back IPO expectations